Home › Trials › NCT06858813

Assessing the effects of ABBV-324 on liver and lung cancers

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

PHASE1 · AbbVie · NCT06858813

This study is testing a new drug called ABBV-324 to see if it can help adults with advanced liver or lung cancer feel better when taken alone or with another medication.

Quick facts

PhasePHASE1
Study typeInterventional
Enrollment232 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie (industry)
Drugs / interventionsatezolizumab, bevacizumab, tremelimumab, durvalumab, lenvatinib, chemotherapy, immunotherapy, radiation
Locations22 sites (Duarte, California and 21 other locations)
Trial IDNCT06858813 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and efficacy of ABBV-324, an investigational drug, in treating adult patients with hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). Participants will be assigned to receive either ABBV-324 alone or in combination with lenvatinib, with the aim of determining the optimal dose and monitoring adverse events. The trial will enroll approximately 232 patients across 45 sites globally, focusing on those with advanced or unresectable disease. The study consists of a dose escalation phase followed by a dose optimization phase to assess the drug's effectiveness.

Who should consider this trial

Good fit: Ideal candidates include adults with advanced hepatocellular cancer or squamous-cell non-small cell lung cancer who meet specific health criteria.

Not a fit: Patients with fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma/HCC will not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced liver and lung cancers.

How similar studies have performed: Other studies have explored similar investigational drugs for these cancers, but the specific approach with ABBV-324 is novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Hepatocellular cancer (HCC) only: Child-Pugh A classification within 7 days before Cycle 1, Day 1 dosing.
* Laboratory values meeting the criteria outlined in the protocol.
* QT interval corrected for heart rate (QTc) \< 470 msec (using Fridericia's correction), no Grade 3 arrythmia, and no other clinically significant cardiac abnormalities.
* Measurable disease per RECIST version 1.1.
* Part 1 and Part 2 - participants with HCC meeting the following disease activity criteria:

  * Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology or cytology. Participants with fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma/HCC are not eligible to enroll.
  * Disease that is not amenable to surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies. For participants who progressed after locoregional therapy for HCC, locoregional therapy must have been completed \>= 28 days prior to baseline scan for the current study.
  * Part 1: Failure of at least 1 prior systemic treatment for HCC.
  * Part 2: Failure of at least 1 prior systemic treatment consisting of an immune checkpoint inhibitor (CPI) containing regimen for HCC, including but not limited to, atezolizumab in combination with bevacizumab or tremelimumab in combination with durvalumab. Note: Participants who have received prior lenvatinib will not be eligible for Part 2.
* Part 1 only - participants with squamous-cell non-small cell lung cancer (LUSC) meeting the following disease activity criteria:

  * Advanced or metastatic LUSC that is not amenable to surgical resection.
  * Must have failed at least 1 prior line of therapy that included at least platinum-based chemotherapy and an immune CPI, and/or an appropriate targeted therapy (if applicable), or is not suitable for other approved therapeutic options that have demonstrated clinical benefit at the judgment of the investigator. Participants should have no more than 2 lines of prior cytotoxic chemotherapy excluding neoadjuvant and/or adjuvant. Participants who are intolerant of standard therapy are eligible.

Exclusion Criteria:

* Unresolved clinically significant adverse events (AEs) \> Grade 1 from prior anticancer therapy except for alopecia.
* Untreated brain or meningeal metastases (i.e., participants with history of metastases are eligible provided they do not require ongoing steroid treatment for cerebral edema and have shown clinical and radiographic stability for at least 14 days after definitive therapy). Participants may continue with antiepileptic therapy if required.
* History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.
* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.
* History of clinically significant, intercurrent lung-specific illnesses including, but not limited to:

  * Underlying pulmonary disorder (i.e., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion, dependence on supplemental oxygen, etc.).
  * Any autoimmune, connective tissue or inflammatory disorders with documented or suspicious pulmonary involvement at Screening.
* Must have discontinued anticancer therapy with antineoplastic intent including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 14 days or 5 half lives of the drug (whichever is shorter) prior to the first dose of ABBV-324. Palliative radiation therapy for bone, skin or subcutaneous metastases with 10 fractions or less is permitted and not participant to a washout period.

Where this trial is running

Duarte, California and 21 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer, LUSC, HCC, ABBV-324, Lenvatinib

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.